OSCO serves as the hub for oncology-related news and advances in Oklahoma. Our organization is made up of clinics and healthcare professionals working together to safeguard the rights of patients and to maintain high medical and ethical standards in the industry.
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma August 25, 2026 Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, establishing a new standard of care in front-line GEA Company to host […]
Read More...
Strategies September 2026 - How Do Cancer Care Professionals Keep Up to Date?
Read More...OSCO invites you to attend our 2026 In-Person Fall Conference, Best of ASCO® Review
Join your colleagues to hear highlights from this state-of-the art symposium featuring national speakers on the experimental biology, etiology, prevention, diagnosis and therapy of cancer.
Your company can sponsor OSCO and the work we do by becoming a corporate member today! For more information or to sign up, contact Kathy Musson, OSCO Executive Director at kmusson@nextwavegroup.net or by phone at 405-261-8188.
The Oklahoma Society of Clinical Oncology (OSCO) is Oklahoma’s only professional organization that represents all those in oncology. Our membership works to advance the sciences of hematology and oncology and its sub-specialties, and to improve services to the public by studying the socio-economic aspects of the practice of our members.
